Dopamine-like Properties of Ephedrine in Rat Brain

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1981 Sep 1

PMID 7196787

Authors

M R Zarrindast

Affiliations

Soon will be listed here.

Abstract

1 Ephedrine (3.1-50 mg/kg) was given intraperitoneally to rats and was found to cause a marked increase in spontaneous locomotor activity. 2 In rats with a unilateral lesion in the substantia nigra made by stereotaxic injections of 6-hydroxydopamine, ephedrine (12.5-150 mg/kg i.p.) caused a dose-dependent turning towards the lesioned side. 3 Turning behaviour and increase in locomotion produced by ephedrine were antagonized by pretreatment of the animals with pimozide, amino-oxyacetic acid or reserpine plus alpha-methyl-p-tyrosine, but not by pretreatment with phenoxybenzamine, propranolol or methergoline. 4 In in vitro studies with synaptosomes prepared from rat brain, ephedrine blocked the uptake and caused the release of [3H]-dopamine. 5 Similar results with regard to locomotion and turning behaviour were obtained with (+)-amphetamine. 6 It is concluded that the increase in locomotion and turning behaviour produced by ephedrine is mediated through an indirect dopaminergic mechanism.

References

Fuxe K, Hokfelt T, Ljungdahl A, Agnati L, Johansson O, Perez de la Mora M . Evidence for an inhibitory gabergic control of the meso-limbic dopamine neurons: possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs. Med Biol. 1975; 53(3):177-83. View

Stevens J, Wilson K, Foote W . GABA blockade, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacologia. 1974; 39(2):105-19. DOI: 10.1007/BF00440842. View

Angrist B, Rotrosen J, Kleinberg D, Merriam V, Gershon S . Dopaminergic agonist properties of ephedrine--theoretical implications. Psychopharmacology (Berl). 1977; 55(2):115-20. DOI: 10.1007/BF01457845. View

HERRIDGE C, ABrook M . Ephedrine psychosis. Br Med J. 1968; 2(5598):160. PMC: 1989207. DOI: 10.1136/bmj.2.5598.160. View

Kruk Z, Zarrindast M . Mazindol anorexia is mediated by activation of dopaminergic mechanisms. Br J Pharmacol. 1976; 58(3):367-72. PMC: 1667599. View

Kane Jr F, FLORENZANO R . Psychosis accompanying use of bronchodilator compound. JAMA. 1971; 215(13):2116. View

Ungerstedt U . Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971; 367:69-93. DOI: 10.1111/j.1365-201x.1971.tb11000.x. View

WALLACH D . Studies on the GABA pathway. I. The inhibition of gamma-aminobutyric acid-alpha-ketoglutaric acid transaminase in vitro and in vivo by U-7524 (amino-oxyacetic acid). Biochem Pharmacol. 1961; 5:323-31. DOI: 10.1016/0006-2952(61)90023-5. View

Roth R, Suhr Y . Mechanism of the gamma-hydroxybutyrate-induced increase in brain dopamine and its relationship to "sleep". Biochem Pharmacol. 1970; 19(12):3001-12. DOI: 10.1016/0006-2952(70)90086-9. View

10.

Snyder S, Banerjee S, Yamamura H, Greenberg D . Drugs, neurotransmitters, and schizophrenia. Science. 1974; 184(4143):1243-53. DOI: 10.1126/science.184.4143.1243. View

11.

ANDEN N . Inhibition of the turnover of the brain dopamine after treatment with the gammaaminobutyrate: 2-oxyglutarate transaminase inhibitor aminooxyacetic acid. Naunyn Schmiedebergs Arch Pharmacol. 1974; 283(4):419-24. DOI: 10.1007/BF00501114. View

12.

Weissman A, KOE B, TENEN S . Antiamphetamine effects following inhibition of tyrosine hydroxylase. J Pharmacol Exp Ther. 1966; 151(3):339-52. View